TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.

<p class="MsoNormal" style="text-align: justify; line-height: 150%; margin: 0cm 0cm 0pt;"><span style="line-height: 150%; font-family: ";Arial";,";sans-serif";; font-size: 10pt; mso-fareast-font-family: Arial; mso-bidi-font-size: 14.0...

Full description

Saved in:
Bibliographic Details
Main Authors: Lionel Ades, Charicleia Kelaidi, Pierre Fenaux
Format: Article
Language:English
Published: PAGEPress Publications 2011-01-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:http://www.mjhid.org/article/view/8840
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846095543415078912
author Lionel Ades
Charicleia Kelaidi
Pierre Fenaux
author_facet Lionel Ades
Charicleia Kelaidi
Pierre Fenaux
author_sort Lionel Ades
collection DOAJ
description <p class="MsoNormal" style="text-align: justify; line-height: 150%; margin: 0cm 0cm 0pt;"><span style="line-height: 150%; font-family: ";Arial";,";sans-serif";; font-size: 10pt; mso-fareast-font-family: Arial; mso-bidi-font-size: 14.0pt;" lang="FR">Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to<span style="mso-spacerun: yes;">  </span>APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.</span></p><p class="MsoNormal" style="text-align: justify; line-height: 150%; margin: 0cm 0cm 0pt;"><span style="line-height: 150%; font-family: ";Arial";,";sans-serif";; font-size: 10pt; mso-fareast-font-family: Arial; mso-bidi-font-size: 14.0pt;" lang="FR"> </span></p>
format Article
id doaj-art-c5cfae22b84d4eecb9b416db1d89d0c4
institution Kabale University
issn 2035-3006
language English
publishDate 2011-01-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-c5cfae22b84d4eecb9b416db1d89d0c42025-01-02T10:23:34ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062011-01-0131e2011038e2011038TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.Lionel AdesCharicleia KelaidiPierre Fenaux<p class="MsoNormal" style="text-align: justify; line-height: 150%; margin: 0cm 0cm 0pt;"><span style="line-height: 150%; font-family: ";Arial";,";sans-serif";; font-size: 10pt; mso-fareast-font-family: Arial; mso-bidi-font-size: 14.0pt;" lang="FR">Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to<span style="mso-spacerun: yes;">  </span>APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.</span></p><p class="MsoNormal" style="text-align: justify; line-height: 150%; margin: 0cm 0cm 0pt;"><span style="line-height: 150%; font-family: ";Arial";,";sans-serif";; font-size: 10pt; mso-fareast-font-family: Arial; mso-bidi-font-size: 14.0pt;" lang="FR"> </span></p>http://www.mjhid.org/article/view/8840Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis
spellingShingle Lionel Ades
Charicleia Kelaidi
Pierre Fenaux
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
Mediterranean Journal of Hematology and Infectious Diseases
Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis
title TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_full TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_fullStr TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_full_unstemmed TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_short TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_sort treatment of acute promyelocytic leukemia with high white cell blood counts
topic Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis
url http://www.mjhid.org/article/view/8840
work_keys_str_mv AT lionelades treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts
AT charicleiakelaidi treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts
AT pierrefenaux treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts